B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for ...

B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers ...

Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...

Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with ...

Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with a Buy recommendation. As of January 28, 2025, the average one-year ...

Foghorn Therapeutics Inc. (FHTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Foghorn Therapeutics Inc. (FHTX) has been beaten down lately with too much selling pressure. While the stock has lost 23.1% over the past four weeks, there is light at the end of the tunnel as it ...

Foghorn Therapeutics Inc. (FHTX) has been beaten down lately with too much selling pressure. While the stock has lost 23.1% ...

Mel Gibson’s chamber thriller Flight Risk is thin at 3,000 feet, but Topher Grace makes for good in-flight entertainment.

The Elwha — which spent over half a century sailing Puget Sound and beyond, sometimes tearing up ferry docks or ramming rocks ...